

- physiology of, 1720, 1721f  
 volume-related properties of, 306e-1-2, 306e-1f  
 work of breathing, 306e-2-3
- Ventral respiratory column, 1720
- Ventricular afterload, 265e-8, 265e-9f
- Ventricular aneurysm, 1610
- Ventricular arrhythmias, **1489**  
 approach to the patient, 1491, 1500  
 characteristics of, 1489-1491, 1490f  
 clinical features of, 1491  
 diagnosis of, 1491, 1492t  
 diseases associated with, 1495t  
 in myocardial infarction, 1608-1609  
 premature ventricular beats. *See* Premature ventricular contractions (PVCs)  
 treatment of, 1498-1500, 1499f  
 ventricular fibrillation. *See* Ventricular fibrillation (VF)  
 ventricular tachycardia. *See* Ventricular tachycardia (VT)
- Ventricular couplets, 1489
- Ventricular dysplasia, arrhythmogenic. *See* Arrhythmogenic right ventricular cardiomyopathy (ARVC)
- Ventricular end-diastolic pressure, 265e-7
- Ventricular end-diastolic volume, 265e-7, 265e-9f
- Ventricular fibrillation (VF)  
 cardiac arrest/sudden cardiac death in, 1764  
 ECG in, 1491f  
 etiology of, 1498  
 in hypothermia, 478e-2, 478e-3  
 in ischemic heart disease, 1580  
 mechanism of, 273e-2, 273e-3t, 273e-4  
 in myocardial infarction, 1608-1609  
 postresuscitation care, 1770  
 treatment of, 1498, 1769, 1769f
- Ventricular filling, assessment of, 265e-10
- Ventricular flutter, 1489. *See also* Ventricular tachycardia
- Ventricular function curve, 265e-7
- Ventricular premature beats, 1580, 1608
- Ventricular remodeling. *See* Left ventricular remodeling
- Ventricular septal defect (VSD)  
 AV conduction block in, 1473  
 cardiac catheterization in, 1463  
 echocardiography in, 270e-25  
 erythrocytosis in, 1523  
 heart sounds/murmur in, 51e-1f, 51e-2-5, 51e-2f, 1449  
 location of, 1521f  
 natural history of, 1522  
 in pregnancy, 47  
 pregnancy and, 1522  
 pulmonary hypertension and, 1522  
 RV outflow tract obstruction in, 1522-1523  
 treatment of, 1523
- Ventricular septal rupture, 1762, 1762t
- Ventricular tachycardia (VT)  
 cardiac arrest/sudden cardiac death in, 1764  
 definition of, 1489  
 implantable cardioverter-defibrillator for, 273e-7  
 incessant, 1498  
 in ischemic heart disease, 1580  
 LV intrafascicular, 1496  
 mechanism of, 273e-3, 273e-3t, 273e-4  
 monomorphic, 278e-13f, 1489, 1490f, 1491f  
 in myocardial infarction, 1608  
 nonsustained  
 characteristics of, 1489, 1490f  
 diagnosis of, 1492  
 diseases associated with, 1493-1494  
 prognosis of, 1491-1492  
 treatment of, 1492-1494  
 outflow tract, 1495-1496  
 polymorphic  
 in Brugada syndrome, 1497-1498. *See also* Brugada syndrome  
 catecholaminergic, 147, 1498  
 diseases associated with, 1496t  
 drug-induced, 43, 1496t  
 in early repolarization syndrome, 1498  
 ECG in, 1491, 1491f, 1497f
- in genetic dilated cardiomyopathy, 1498  
 in hypertrophic cardiomyopathy, 1498  
 in long QT syndrome, 147, 1497, 1497f. *See also* Long QT syndrome  
 mechanism of, 273e-3t, 273e-4  
 in myocardial infarction/ischemia, 1496, 1608  
 in short QT syndrome, 1497  
 sinusoidal, 1489, 1491f  
 sustained monomorphic  
 characteristics of, 1489, 1491f, 1494  
 diagnosis of, 1494  
 diseases associated with, 1494-1496, 1496t  
 idiopathic, 1495-1496  
 in myocardial infarction, 1608  
 prognosis of, 1494  
 vs. supraventricular tachycardia, 1494, 1494f  
 treatment of, 1494-1496  
 treatment of  
 antiarrhythmic drugs, 1498-1499  
 catheter ablation, 1499-1500  
 implantable cardioverter-defibrillators, 1499, 1499f  
 ventricular fibrillation. *See* Ventricular fibrillation (VF)  
 ventricular flutter, 1489, 1491f
- Ventriculography, 1463-1464, 1464f
- Ventriculostomy, 1779, 1780f
- VEPs (visual evoked potentials), 442e-3
- Verapamil  
 for accessory pathway-mediated tachycardia, 1483  
 adverse effects of, 1589t, 2595-2596, 2640t  
 for aortic dissection, 1641  
 for arrhythmias, 1479t, 1480t  
 for atrial fibrillation, 1487  
 for AV nodal reentrant tachycardia, 1479  
 for cluster headache prevention, 2595, 2595t  
 dosage of, 1479t, 1480t  
 drug interactions of, 34t  
 azoles, 246e-3t  
 digoxin, 42t  
 quinidine, 246e-6t  
 ranolazine, 1590  
 for hypertension, 1624t, 1625, 1821  
 for hypnic headache, 2598  
 for insulinoma, 569  
 for ischemic heart disease, 1589t  
 metabolism of, 34, 34t  
 for NSTEMI-ACS, 1596  
 overdose/poisoning with, 473e-9t  
 pharmacology of, 1479t, 1480t  
 for supraventricular arrhythmia, 1609
- Vermiculite dust, 1690
- Verner-Morrison syndrome. *See* VIPoma (vasoactive intestinal peptidoma)
- Verruca plana, 342f
- Verruca vulgaris, 342f, 351
- Verruga peruana, 829, 1081t, 1083
- Vertebrae  
 anatomy of, 111, 112f  
 "ivory," 426e-2  
 ligament injury, 441e-33f  
 "picture frame," 426e-2  
 "squaring" of, 2169
- Vertebral artery, occlusion of, 2575-2577
- Vertebral fractures  
 epidemiology of, 2488-2489, 2488f, 2489f  
 estrogen deficiency and, 2492  
 imaging in, 441e-31-34f  
 in osteoporosis, 117  
 pain in, 117, 2495  
 prevention of  
 bisphosphonates for, 2499-2500, 2500f  
 denosumab for, 2501, 2502f  
 teriparatide for, 2502, 2502f  
 treatment of, 2495
- Vertebral osteomyelitis. *See* Osteomyelitis, vertebral
- Vertebroplasty, 2503
- Vertigo, **148**  
 acute prolonged (vestibular neuritis), 149  
 approach to the patient, 148-149
- benign paroxysmal positional, 149t, 150, 150f  
 central, 149t  
 evoked by loud sounds, 219  
 in Ménière's disease. *See* Ménière's disease in migraine, 150  
 in MS, 2663  
 peripheral, 149t  
 prevention of, 151  
 psychosomatic, 151  
 treatment of, 151, 151t  
 in vestibular dysfunction, 149, 150-151
- Very-low-calorie diet, 2396
- Very-low-density lipoproteins (VLDLs)  
 characteristics of, 1241t, 2436-2437, 2436f  
 estimate of, 2446  
 overproduction of, 2438-2439, 2451. *See also* Lipoprotein disorders  
 in transport of hepatic lipids, 2437, 2437f
- Vesicants, **262e-1**, 262e-1t
- Vesicles/bullae, 339t, **361**  
 clinical features of, 341t  
 description of, 127, 339t  
 drug-induced, 361  
 etiology of, 361-362, 361t, 827, 828t, 829  
 with fever, 131-132t, 134-135  
 in herpes simplex virus infections. *See* Herpes simplex virus (HSV) infections  
 infections associated with, 827, 828t, 829  
 in smallpox. *See* Smallpox  
 in varicella. *See* Varicella (chickenpox)
- Vesicoureteral reflux, 1859-1860, 1860f, 1871
- Vesiculoviruses, 1305, 1310t
- Vesiculovirus infections  
 Chandipura virus, 1316  
 vesicular stomatitis viruses, 1299, 1304, 1310t
- Vessel wall, 725, 732
- Vestibular dysfunction, 149, 149t, 151, 164
- Vestibular-evoked myogenic potential test, 223
- Vestibular migraine, 150
- Vestibular neuritis, 149, 149t. *See also* Vertigo
- Vestibular nystagmus, 210
- Vestibular rehabilitation therapy, 151
- Vestibular schwannoma (acoustic neuroma)  
 diagnosis of, 149, 150, 220, 603  
 facial nerve involvement in, 2648  
 hearing loss in, 150, 220, 222  
 imaging in, 223  
 in neurofibromatosis, 603, 603f, 604, 2343
- Vestibulocochlear nerve, 2538
- Vestibuloocular reflex, 149
- Vestibulopathy, acute peripheral, 149
- Vestibulospinal pathway, 155f
- Veterans. *See* War veterans
- VHL gene mutations  
 action of, 2329, 2332, 2343  
 epigenetic silencing of, 102e-7  
 in pheochromocytoma/paraganglioma, 2334f, 2335  
 in renal cell carcinoma, 578  
 in von Hippel-Lindau disease/syndrome. *See* von Hippel-Lindau disease/syndrome, genetic considerations in
- VHL protein, 2329
- Vibration injury, 1649
- Vibration sense, 159, 160t, 2539
- Vibratory angioedema, 2118
- Vibrio alginolyticus* infections, 1065t, 1066
- Vibrio cholerae*. *See also* Cholera  
 adherence of, 145e-3, 852  
 epidemiology of, 1061-1062, 1062f  
 genome of, 777, 777f, 1063  
 laboratory identification of, 150e-2t, 1063  
 microbiology of, 1061  
 non-O1/O139, 1065-1066, 1065t  
 serotypes of, 1061-1062  
 toxin production by, 1062-1063
- Vibrio parahaemolyticus* infections, 151e-8, 856t, 1065, 1065t
- Vibrio vulnificus* infections, **1066**  
 clinical features of, 132t, 135, 782, 1066, 1755  
 epidemiology of, 1065t, 1066  
 treatment of, 1066